US Endoscopic Bariatric Therapies Market Industry Trends and Forecast to 2034: Segmented by (Procedure, Product, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
US · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$278.8 MnPlaceholder estimate
Estimate 2025$307.6 Mn40.9% of the global market
Projected 2034$743.2 Mn 141.6%Adds $435.6 Mn over 9 forecast years
CAGR 2025–203410.3%Faster than 81% of 180 Medical Devices markets here
Key players5
US is 40.86% of the global market.
In North America, the largest is US (this report) at $307.6 Mn.
19 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The US Endoscopic Bariatric Therapies Market Analysis Executive Summary
Endoscopic bariatric therapies are weight-loss procedures done through the mouth with a flexible scope, without cuts in the skin.
Key segments of the endoscopic Bariatric Therapies market include procedure (Endoscopic Sleeve Gastroplasty, Intragastric Balloon and Duodenal Mucosal Resurfacing) and product (Suturing Systems, Balloons and Liners).
US Endoscopic Bariatric Therapies market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
US Endoscopic Bariatric Therapies Market Dynamics
Market Growth Drivers
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the endoscopic Bariatric Therapies market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Opportunity
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the endoscopic Bariatric Therapies market, especially in fast-growing emerging economies.
Market Restraints
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the endoscopic Bariatric Therapies market. Long-term safety data and lifestyle support are still needed for many patients.
Competitive Landscape for Endoscopic Bariatric Therapies Market in the US
The endoscopic Bariatric Therapies market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Endoscopic Bariatric Therapies Market in the US
Endoscopic Bariatric Therapies in the US: rules, payment and research
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA).[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[2] ClinicalTrials.gov lists 19 studies on Endoscopic Bariatric Therapies that are recruiting, active or about to start in the US.[3] Obesity (adults): 41.0% of adults in 2024, the latest WHO figure for the US.[4]
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how endoscopic Bariatric Therapies products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in the US.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Procedure
4.2 By Product
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Boston Scientific
7.2 Apollo Endosurgery
7.3 Fractyl Health
7.4 GI Dynamics
7.5 Olympus Corporation
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The endoscopic Bariatric Therapies market can be segmented based on various criteria, including procedure, product and end user. Here's a breakdown of the market segmentation
How big is the Endoscopic Bariatric Therapies market in the US?
Placeholder estimate: about $307.6 Mn in 2025, rising to about $743.2 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Endoscopic Bariatric Therapies market in the US growing?
Placeholder estimate: about 10.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Endoscopic Bariatric Therapies market report cover?
The report splits the market by procedure (Endoscopic Sleeve Gastroplasty, Intragastric Balloon, Duodenal Mucosal Resurfacing, Aspiration Therapy), product (Suturing Systems, Balloons, Liners) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Endoscopic Bariatric Therapies market?
Key players include Boston Scientific Corporation, Apollo Endosurgery, Fractyl Health, GI Dynamics and Olympus Corporation.
What is driving the Endoscopic Bariatric Therapies market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the endoscopic Bariatric Therapies market.
Who regulates Endoscopic Bariatric Therapies in the US?
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA). Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Endoscopic Bariatric Therapies are running in the US?
19 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
What does WHO report for the US?
Obesity (adults): 41.0% of adults in 2024, the latest WHO figure. Source: WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 20 Nov 2026.
How many people in the US are 65 or older?
18.4% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 19 Nov 2026.